Current aspects with regard to the link between pregnancy and inflammatory bowel disease by Prelipcean Cijevschi Cristina et al.
Arch. Biol. Sci., Belgrade, 66 (3), 1047-1054, 2014 DOI:10.2298/ABS1403047P
1047
CURRENT ASPECTS WITH REGARD TO THE LINK BETWEEN PREGNANCY AND  
INFLAMMATORY BOWEL DISEASE
CRISTINA CIJEVSCHI PRELIPCEAN1, CATALINA MIHAI1, P. GOGALNICEANU2,  
CARMEN ANTON1 and E. ANTON3
1University of Medicine and Pharmacy “Gr. T. Popa”, Center of Gastroenterology and Hepatology, Iasi, Romania 
2London Postgraduate School of Surgery, London, United Kingdom 
3University of Medicine and Pharmacy “Gr. T. Popa”, Iasi, Romania
Abstract – Inflammatory bowel disease (IBD) has a high incidence predominantly in young individuals, it also affects 
family planning and pregnancy. In this review we will summarize a number of issues and challenges that arise from this, 
such as the chances of having a successful pregnancy, how IBD affects pregnancy, what investigations are needed during 
pregnancy, as well as what is the correct management of IBD (dietary, medical or surgical) in pregnant women with this 
disorder. IBD in pregnancy requires a multidisciplinary approach involving close collaboration between patient, gynecolo-
gist and gastroenterologist in order to increase treatment compliance and facilitate a successful pregnancy.
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INTRODUCTION
Inflammatory bowel disease (IBD) consists of ulcer-
ative colitis (UC) and Crohn’s Disease (CD). These 
are complex, chronic conditions featuring frequent 
relapses. They pose a diagnostic challenge, are of var-
ious levels of intensity and are incurable, and have an 
unpredictable therapeutic response. IBD predomi-
nantly affects younger individuals, and concurrent 
pregnancy is often found in this patient group. The 
issues and challenges arising in regard to the relation-
ship between pregnancy and IBD will be examined.
The chances of having a successful pregnancy in the 
context of IBD
Current literature suggests that fertility in IBD suf-
ferers is similar in both women and men when com-
pared  to  the  general  population  prior  to  surgical 
interventions (Lepistö et al., 2007), as well as dur-
ing disease remission (van der Woude et al., 2010). 
The reduction in births in the IBD population does 
not appear to be directly linked to the disease itself. 
Moreover, the disease should be in remission for 3-6 
months prior to conception. The chances of an acute 
exacerbation of IBD are around 33%, irrespective of 
pregnant status (Sunanda et al., 2010). The patient 
must be compliant with the treatment of any acute 
exacerbations, as the maintenance of disease remis-
sion is essential to a normal pregnancy. Additionally, 
the pregnant patient must be monitored every three 
months or more often if needed by a multidiscipli-
nary team including both obstetricians and gyne-
cologists.1048 CRISTINA CIJEVSCHI PRELIPCEAN ET AL.
In CD, the infertility seen during disease remis-
sion is also similar to that of the general population 
(5-14%) (Hudson et al., 2007). This is not the same 
during  active  forms  of  the  disease,  where  fertility 
rates range between 40-80%. This may be explained 
by the inflammatory process that may involve the 
ovaries and annexes, and post-operative adhesions 
that may involve the anterior aspects of the pelvis. In 
addition, secondary amenorrhea may occur because 
of malabsorption or a severe episode of disease ex-
acerbation, as well as by changes in sexual behavior 
patterns due to anoperineal lesions leading to dys-
pareunia (Munkholm et al., 2000).
In UC, fertility falls by 40-80% following surgi-
cal interventions such as proctocolectomies and es-
pecially ileoanal pouch reconstructions. This may be 
attributed to the higher incidence of hydrosalpynx, 
fimbria destruction or fallopian tube blockage (Ver-
meire et al., 2010). Consequently, females with se-
vere forms of UC need to be actively involved in the 
decision-making process of choosing medical and 
surgical management options.
Controversy exists as to whether surgical inter-
vention should be via an open or laparoscopic ap-
proach. There is also a lack of consensus regarding the 
role of laparoscopy in reducing the risk of infertility 
(Serafi et al., 2012). A possible explanation could be 
represented by the role of relaxin in inhibiting mac-
rophage function and subsequently reducing the risk 
of adhesion formation (Munkholm et al., 2000).
Regarding male fertility, pelvic surgery and es-
pecially undergoing ileoanal pouch reconstruction 
can lead to ejaculatory or erectile dysfunction due 
to damage to the autonomic nervous system (Dam-
gaard  et  al.,  1995).  Consequently,  sperm  storage 
must be considered prior to surgery. Sulfasalazine 
used in moderate forms of the disease can lead to a 
decrease in the number and motility of sperm cells; 
however, this is completely reversible at 6 months 
following  therapy  cessation  (Levi  et  al.,  1979). 
Methotrexate also leads to oligospermia and must 
be stopped for 4 months prior to conception (Suna-
nda et al., 2010).
The chances of having a healthy child
The etiology of IBD depends on genetic predisposi-
tion and environmental triggers; 5.5-22% of IBD suf-
ferers have a family member already suffering from 
IBD. 
In cases where both parents are IBD sufferers, 
their children have a 36% lifetime risk of developing 
it (Bennet et al., 1991). If one parent suffers from IBD, 
offspring have a 2-13-fold higher risk of developing 
the disease compared to the general population (Ma-
hadevan et al., 2006). The risk is higher for 1st degree 
relatives for developing CD (5.2%) compared to UC 
(1.6%). In addition, the risk for 1st degree relatives 
is slightly higher in the Jewish population (Serafi et 
al., 2012). Patients with IBD that have a positive fam-
ily history tend to develop the disease at an earlier 
age compared to those without UC (Laharie et al., 
2001).
The relationship between IBD and pregnancy
There is a lack of consensus regarding the role of 
IBD in pregnancy. Patients with disease remission 
or mild forms of IBD have normal pregnancies (Su-
nanda et al., 2010). It is known that surgical resec-
tion and ileal involvement are risk factors for com-
plications of pregnancy. Some studies support the 
view that the presence of IBD is associated with a 
higher risk of complications, irrespective of disease 
severity, with CD being more detrimental than UC 
(Mahadevan et al., 2007). Consequently, premature 
birth (<37 weeks) is more often found in patients 
with active IBD. In CD sufferers, premature birth is 
3.4 times more likely in those with active CD. Simi-
larly, a reduced birth rate (2 500-2 700 g) occurs 
irrespective of disease severity, especially in those 
with CD (Sunanda et al., 2010). Delayed intra-uter-
ine growth and spontaneous or therapeutic abor-
tions are also seen more often than in the general 
population.  Pregnant  women  suffering  from  IBD 
have fewer surgical procedures compared to those 
with IBD who are not pregnant. This may be ex-
plained by the role relaxin, a pregnancy hormone 
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through macrophage inhibition during pregnancy 
(Nguyen et al., 2009).
If pregnancy occurs during a period of IBD re-
mission, the risk of acute exacerbations is similar in 
both pregnant and non-pregnant patients (Serafi et 
al., 2012). In contrast, if the patient becomes preg-
nant during an episode of active disease, two thirds 
of the patients will maintain their active status dur-
ing the entire pregnancy. This is an important factor 
in patient education, as individuals must be coun-
seled regarding the need to commence a pregnancy 
during an episode of remission.
Investigations required during pregnancy
In this case as well there is a lack of consensus in 
the existing literature. Diagnostic and therapeutic 
endoscopy is a feasible alternative to radiological 
imaging in pregnant patients. Any invasive endo-
scopic  procedure  carried  out  requires  periopera-
tive fetal heart rate monitoring. A total colonoscopy 
is not advocated during pregnancy, where flexible 
sigmoidoscopy should be the first line investigation 
modality. A total colonoscopy may be justified if ab-
solutely necessary to assess the severity of an acute 
exacerbation, an acute gastrointestinal bleed or to 
investigate diarrheal episodes only after a flexible 
sigmoidoscopy has been inconclusive. Bowel prepa-
ration is achieved using polyethylene glycol solu-
tion  (Rimensberger  et  al.,  1992).  Intraprocedural 
monitoring  may  require  maternal  blood  pressure 
monitoring and arterial blood gas analysis to insure 
adequate oxygenation and placental perfusion. The 
pregnant patient must be placed in the left lateral 
decubitus position to avoid compression of the in-
ferior vena cava and hypotension (Sunanda et al., 
2010). Upper gastrointestinal endoscopy poses an 
additional risk of aspiration due to the incompe-
tence of the inferior esophageal sphincter during 
pregnancy.  Endoscopic  retrograde  cholangiopan-
creatography (ERCP) is a relatively safe procedure if 
there are strong indications for its use; studies on a 
limited number of patients have not demonstrated a 
rise in fetal malformations or premature births due 
to its use (Cappell et al., 2003). The radiation dose 
used must be greater than 10mGy (Akcakaya et al., 
2009). The risk of post-ERCP pancreatitis must al-
ways be considered in these cases. MRI may be used 
if indicated as it does not involve ionizing radiation 
and can diagnose IBD, as well as monitor its evolu-
tion in the second and third trimester of pregnan-
cy.
The decision to sedate the patient must be care-
fully considered. Pethidine or meperidine may be 
used in the first trimester of pregnancy, as it is often 
used for analgesia and sedation during endoscopy. 
However, it can cause reversible bradycardia in the 
fetus. Fentanyl has also been reported to cause res-
piratory depression and rigidity of the respiratory 
muscles in preterm infants after childbirth (Linde-
mann et al., 1998).
The risk of venous thromboembolism in pregnant 
women with IBD
IBD carries a 4- to 6-fold increased risk of throm-
boembolism during pregnancy, which is an impor-
tant cause of maternal death (Heit et al., 2005). This 
risk is highest in the first 6 weeks of pregnancy and in 
the postnatal period. Consequently, during an acute 
flare of IBD, thromboprophylaxis with low molecu-
lar-weight heparin is recommended during hospital-
ization and in the perioperative period. This has been 
shown to reduce the risk of thromboprophylaxis by 
60-70% (National Clinical Guideline Centre, 2010).
The optimal method of childbirth
IBD is not an indication for caesarean section. De-
spite this, retrospective studies have suggested that 
in CD with perianal involvement there is a risk of 
disease flare-up following vaginal delivery in 18% of 
cases (Kane et al., 2011). A growing trend for caesar-
ean sections has however been noted in IBD sufferers 
(van der Woude et al., 2010).
Management of pregnant women with IBD?
As regards diet, in the severe forms of IBD correc-
tions of electrolytes and fluid balance are essential. 1050 CRISTINA CIJEVSCHI PRELIPCEAN ET AL.
Bowel rest and parenteral nutrition may be used in 
certain  cases.  Smoking  is  contraindicated  during 
pregnancy for fetal and maternal health reasons, de-
spite its impact on UC.
The major risk to pregnancy is caused by IBD ac-
tivity rather than its medical management. There are 
a limited number of studies investigating the impact 
of IBD pharmacotherapy on pregnancy. Drugs used 
can be divided in four categories: A – no risk for the 
fetus; B – no risk demonstrated on humans; possible 
but low risk; C – high risk to the fetus; and D – con-
traindicated during pregnancy. Mesalazine, corticos-
teroids, infliximab and adalimumab are classified as 
category B drugs. Ciprofloxacin and cyclosporin are 
class C agents, whilst azathioprine and 6-mercaptop-
urine are classified as category D drugs.
Thus, sulfasalazine and 5-ASA agents are used 
in the treatment of moderate forms of IBD, as well 
as in maintaining disease remission. They are clas-
sified as class B agents and although they cross the 
placental barrier, they do not lead to fetal malforma-
tions. Sulfasalazine is one of the oldest drugs used 
in the management of IBD and carries the same risk 
profile irrespective of pregnant status. This may in-
clude nausea, vomiting, rashes, anorexia, interstitial 
nephropathy and hepatotoxicity. Consequently, the 
initial starting dose of 500 mg needs to be gradually 
increased. Sulfasalazine can be used in women that 
are breastfeeding. It can interfere with folate absorp-
tion and it must be used in conjunction with folate 
supplementation (2g once daily) prior to conception 
and for the entire duration of the pregnancy (Ver-
meire et al., 2010).
In regards to 5-aminosalicylic acid agents, they 
have  a  similar  side-effect  profile  to  sulfasalazine. 
Nevertheless, their side effects are less frequent and 
severe. Mesalazine can be administered in different 
forms in order to target selectively the part of the GI 
tract affected by IBD. Asacol releases 5-aminosalicyl-
ic acid in the distal ileum and colon, and can be used 
in IBD affecting the distal digestive tract. Pentasa 
causes drug release throughout the entire gastroin-
testinal tract and is used in the management of CD 
affecting the stomach and small bowel. In contrast, 
balsalazine releases 5’-aminosalicylic acid in the co-
lon. Pentasa and balsalazine can be given to pregnant 
women at a maximum dose of 3 g per day, as sug-
gested by meta-analytical work and the ECCO Con-
sensus, without increasing the risk of teratogenicity 
or complications of pregnancy (Kowitz et al., 2004). 
Recently, Asacol has been reclassified from a class B 
to a class C agent due to compounds in its coating 
(van der Woude et al., 2004). The use of mesalazine 
requires further investigation.
Corticosteroid therapy can be used in the treat-
ment of acute flares of IBD in pregnant patients. 
These cross the placenta and are converted into less 
active  compounds  by  11-hydroxygenase,  leading 
to a lower fetal serum concentration. Corticoster-
oids with a short half-life should be administered 
(prednisolone and methylprednisolone) rather than 
those with longer half-lives (e.g. dexamethasone). 
Oral prednisolone (40 mg) can be used as a first-
line agent. In severe cases or in the presence of drug 
tolerance, intravenous hydrocortisone (300 mg) or 
methylprednisolone  can  be  administered.  These 
may be converted to oral prednisolone (30 mg) after 
7 days. In IBD cases involving the left colon, hydro-
cortisone enemas may be used. The side effects of 
prednisolone are well known; however, it is impor-
tant to mention the need to actively monitor elec-
trolytes and reduce salt intake during pregnancy as 
hyponatremia, electrolyte disturbance and hypervo-
lemia can lead to preeclampsia. There is also a risk 
of premature membrane rupture and corticosuprar-
enal insufficiency in the newborn if prednisolone is 
administered in the last trimester of pregnancy, due 
to suppression of the adrenal gland medulla (Homar 
et al., 2008). In the first trimester, the use of corticos-
teroids can lead to orofacial malformations (cleft lip 
and palate) (Moffat et al., 2007). Prednisolone and 
methylprednisolone can however be given during 
lactation. In addition, budesonide, a synthetic ster-
oid, may be used in pregnant women with IBD with-
out complications to the pregnancy or teratogenic 
effects. However, its administration cannot be fully 
endorsed due to its relatively limited use (Beaulieu 
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With  regard  to  immunosuppressants,  azathio-
prine  and  its  metabolite,  6-mercaptupruine,  are 
used in cases that do not respond to 5-ASA and/
or maintenance of long-term remission. These are 
classified as class D drugs from a complications pro-
file perspective. Most studies have shown that their 
use is safe during pregnancy and does not lead to 
an increased risk of malformations in the newborn 
(Cleary et al., 2009). These agents cross the placenta 
and their metabolites can be found in similar quan-
tities in maternal and fetal erythrocytes (Jharap et 
al., 2008). Side effects occur in pregnant and non-
pregnant women to a similar extent. These include 
leucopoenia,  pancreatitis,  nausea  and  vomiting.  It 
is difficult to determine to what extent spontaneous 
abortions, premature births and low birth weight are 
due to therapy with ASA and 6-mercaptopurine or 
IBD itself. The largest study to date was performed 
on a small number of patients, with no significant 
difference in prematurity, spontaneous abortions or 
congenital anomalies in patients with and without 
6-mercaptupurine therapy during pregnancy (Fran-
cella et al., 2003). Current literature does however 
suggest that chromosomal anomalies may occur sec-
ondary to immunosuppression (Coelho et al., 2010). 
Breastfeeding is theoretically contraindicated due to 
the risk of toxicity, infection and pancreatitis in the 
newborn. Despite this, other evidence suggests that 
breastfeeding can be carried out at 4-6 h from the 
last dose of 6-mercaptopurine (the maximal interval 
for excretion of 6-mercaptopurine in maternal milk) 
(Serafi et al., 2012).
Cyclosporin is used in treating fulminant UC as 
an alternative to colectomy, which is associated with 
an increased fetal mortality (Branche et al., 2009). 
Cyclosporin is not thought to be teratogenic but it 
is reserved for severe cases and its use in pregnan-
cy is extremely rare (Bar-Oz et al., 2001). There are 
no teratogenic side effects described for tacrolimus. 
Furthermore, it is difficult to determine whether the 
low birth weight and prematurity noted are caused 
by the severity of the disease or the medical therapy 
administered.  Currently,  there  is  one  case  of  IBD 
(UC) treated with tacrolimus in a pregnant patient 
(Baunergart et al., 2005).
Methotrexate and thalidomide are used in pa-
tients  with  IBD  that  are  resistant  to  conventional 
management. Importantly, they are teratogenic and 
contraindicated  in  pregnancy.  Methotrexate  given 
in the first trimester of pregnancy leads to abortion, 
congenital  malformation  and  development  abnor-
malities  of  the  nervous  system  (Kozlowski  et  al., 
1990). It is important to note that methotrexate has 
a long half-life and its use is contraindicated for 3-6 
months prior to conception in both men and women. 
Accidental pregnancies during methotrexate therapy 
may  require  a  therapeutic  abortion.  Thalidomide 
is  an  alternative  IBD  treatment  modality  through 
its anti-tumor necrosis factor (TNF) and anti-ang-
iogenic effects. It leads to fetal malformations and a 
high rate of neonatal mortality (approximately 40%) 
(Smithells et al., 1992). Female IBD patients on tha-
lidomide therapy should be on a dual contraceptive 
therapy.
Regarding  antibiotics,  ciprofloxacin  and  met-
ronidazole  are  used  electively  in  the  treatment  of 
pouchitis and perianal CD. Metronidazole is class B 
agent used in the management of IBD in pregnan-
cy; its use is safe in the second and third trimesters 
of  pregnancy,  although  the  development  of  facial 
malformations have been documented (Piper et al., 
1993). Ciprofloxacin is considered a class C agent. 
It has not been shown to lead to spontaneous abor-
tions or the development of congenital anomalies in 
clinical studies. Animal studies have suggested the 
possible development of skeletal muscle anomalies 
following its use. During pregnancy, the use of safer 
antimicrobials is recommended for the treatment of 
pouchitis. These include ampicillin, cephalosporins 
and amoxicillin with clavulanic acid.
Agents with anti-TNFα activity (infliximab, adal-
imumab, certolizumab pegol) actively cross the pla-
cental barrier by using specific fetal receptors. This 
occurs most significantly in the third trimester and 
can be detected in the newborn for up to 6 months, 
often at a higher level than in the maternal blood 
(Mahadevan et al., 2007). Consequently, in patients 
in remission, infliximab therapy should be stopped 
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not be vaccinated for 6 months with agents using 
live or live attenuated micro-organisms (rotavirus, 
measles,  rubella,  BCG,  mumps  and  chickenpox) 
(Zelinkova et al., 2011). In addition, the GETAID 
and TREAT studies did not identify any differences 
in fetal or maternal complication in patients treated 
with or without infliximab (Reddy et al., 2008). The 
same applies for adalimumab therapy despite a more 
limited evidence basis (Vesga et al., 2009). The use of 
certolizumab in pregnant IBD-suffers is even scarcer. 
It is believed that the placental transport is minimal 
and passive and does not lead to fetal abnormalities. 
Consequently, a normal vaccination pattern may be 
adopted (Kane et al., 2011).
Adjuvant  therapy  with  an  antidiarrheal  agent, 
such as loperamide, can be used in pregnant IBD-
suffers.
Regarding  surgical  management,  this  is  rela-
tively safe throughout the duration of the pregnancy. 
A small number of patients have identified a risk of 
abortion  during  the  first  trimester  and  premature 
birth in the third trimester in IBD patients under-
going  surgery  (Serafi  et  al.,  2012).  Indications  for 
surgery are the same in pregnant and non-pregnant 
IBD patients, i.e. bowel obstruction in CD, intestinal 
bleeding, perforation and abscesses in fulminant UC 
that do not respond to medical therapy and where 
the risk posed by the disease severity is greater than 
that of the surgery (van der Woude et al., 2010).
Breastfeeding in patients with IBD
Breastfeeding is beneficial for both mother and baby 
in healthy individuals. It has a variable impact on 
conditions with an immune etiology. In cases such 
as multiple sclerosis or rheumatoid arthritis, breast-
feeding  may  lead  to  exacerbations  of  the  disease, 
whilst in IBD it can have a protective role for the 
mother, as well as for the fetus. In the mother, this 
is manifested as a longer duration of disease remis-
sion and in the fetus by a delay in the onset of IBD 
(American Academy of Pediatrics Work Group on 
Breastfeeding, 1997). These can be explained by a re-
duction in estrogen and progesterone levels during 
lactation, leading to a reduction in the pro-inflam-
matory response sustained by the intestinal mucosa 
(Bergstrand et al., 2003). Another explanation is the 
psychosomatic effect of breastfeeding during which 
women experience reduced levels of stress and post-
partum anxiety. This leads to raised levels of corti-
cotropin-releasing  factor,  which  can  modulate  in-
flammatory responses and reduces the onset of acute 
exacerbations (Moffat et al., 2004). 14-85% of moth-
ers with IBD self-interrupt their medical therapy dur-
ing lactation. Clinicians need to explain to patients 
that breastfeeding is safe when taking certain classes 
of drugs. 5-ASA (sulfasalazine, mesalazine; 3 g/day) 
are compatible with breastfeeding. Possible compli-
cations are diarrhea in the fetus (Hart et al., 2010). 
Corticosteroids with a short half-life (prednisolone, 
methylprednisolone) can be used safely during lacta-
tion (Moffat et al., 2004). Traditionally, azathioprine 
and 6-marcaptopuine were contraindicated during 
breastfeeding. Pharmacokinetic studies suggest that 
breastfeeding can take place 4-5 h after the use of 
immunomodulator therapy, as there is limited ex-
cretion in maternal milk (Christensen et al., 2008). 
Cyclosporine, methotrexate, tacrolimus and thalido-
mide are also contraindicated during breastfeeding 
(Hart et al., 2010). Biological agents are not excreted 
in maternal milk and can be safely used (Stengel et 
al., 2008). The most commonly studied agent is in-
fliximab. In addition, antibiotic use needs to be ad-
justed, with ciprofloxacin and metronidazole being 
exchanged  for  ampicillin  and  amoxicillin,  which 
have less toxic side effects during lactation.
CONCLUSIONS
IBD has a high incidence predominantly in young 
individuals and therefore has a concomitant impact 
on family planning and pregnancy. Ideally, concep-
tion needs to occur during remission of IBD and cli-
nicians must strive to maintain this throughout the 
entire pregnancy. The highest risk to the pregnant 
patient and fetus is posed by the disease, not by dis-
ease therapy. In the postnatal period, management 
of IBD needs to be tailored to lactation priorities. 
IBD  management  in  pregnancy  requires  a  multi-
disciplinary approach, involving close collaboration CURRENT ASPECTS REGARDING THE CONNECTION BETWEEN PREGNANCY AND INFLAMMATORY BOWEL DISEASE 1053
between patient, gynecologist and gastroenterologist 
in order to increase treatment compliance and a suc-
cessful pregnancy.
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